Checkpoint Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Checkpoint Therapeutics
CKPT Stock  USD 3.99  0.02  0.50%   
Checkpoint Therapeutics financial statements provide useful quarterly and yearly information to potential Checkpoint Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Checkpoint Therapeutics financial statements helps investors assess Checkpoint Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Checkpoint Therapeutics' valuation are summarized below:
Gross Profit
-27.6 M
Market Capitalization
219.4 M
Enterprise Value Revenue
4.6 K
Revenue
47 K
Earnings Share
(1.83)
There are currently one hundred twenty fundamental signals for Checkpoint Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Checkpoint Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 77.3 M in 2025, whereas Market Cap is likely to drop slightly above 46.9 M in 2025.

Checkpoint Therapeutics Total Revenue

88,065

Check Checkpoint Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Checkpoint Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 102.1 K, Depreciation And Amortization of 183.4 K or Interest Expense of 5.2 M, as well as many indicators such as Price To Sales Ratio of 394, Dividend Yield of 0.0 or Days Sales Outstanding of 168. Checkpoint financial statements analysis is a perfect complement when working with Checkpoint Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Checkpoint Therapeutics Correlation against competitors.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Checkpoint Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding22.6 M21.6 M9.3 M
Slightly volatile
Short and Long Term Debt Total2 M2.2 M2.4 M
Slightly volatile
Cash And Short Term Investments4.2 M4.4 M32.9 M
Slightly volatile
Long Term Debt Total2 M2.2 M2.4 M
Slightly volatile
Liabilities And Stockholders Equity4.6 M4.8 M33.7 M
Slightly volatile
Capital Surpluse133 M256.5 M123.9 M
Slightly volatile
Capital Stock4 K2.7 K4.3 K
Very volatile

Checkpoint Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income102.1 K138.6 K159.7 K
Slightly volatile
Depreciation And Amortization183.4 K193.1 K374.4 K
Slightly volatile
Selling General Administrative7.3 M10 M5.6 M
Slightly volatile
Total Revenue88.1 K92.7 K928.9 K
Pretty Stable
Other Operating Expenses39.3 M60.1 M30.6 M
Slightly volatile
Research Development32 M50.1 M25 M
Slightly volatile
Cost Of Revenue32 M50.1 M25 M
Slightly volatile
Total Operating Expenses39.3 M60.1 M30.6 M
Slightly volatile
Non Operating Income Net Other45.3 K47.7 K81.8 K
Very volatile
Selling And Marketing Expenses280 K270 K378.1 K
Slightly volatile

Checkpoint Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.4 M2.6 M3 M
Slightly volatile
Depreciation227.2 K372.6 K232.9 K
Slightly volatile
Other Non Cash Items4.3 M3.7 M6 M
Slightly volatile
End Period Cash Flow4.2 M4.4 M32.9 M
Slightly volatile
Change To Netincome5.6 M9.7 M8.8 M
Slightly volatile
Cash Flows Other Operating4.5 M8.5 M6 M
Pretty Stable
Issuance Of Capital Stock35.2 M47.5 M32.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio394375241
Slightly volatile
Days Sales Outstanding16816076.7283
Slightly volatile
Stock Based Compensation To Revenue26.5825.319.2706
Slightly volatile
Capex To Depreciation7.88.789.5702
Slightly volatile
EV To Sales349332180
Slightly volatile
Days Of Inventory On Hand0.00.00.0
Slightly volatile
Payables Turnover6.627.638.1378
Slightly volatile
Sales General And Administrative To Revenue79.6875.8922.5478
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue400381113
Slightly volatile
Capex To Revenue0.250.271.8157
Slightly volatile
Cash Per Share0.290.311.2773
Slightly volatile
Days Payables Outstanding57.3849.5456.269
Slightly volatile
Income Quality0.510.830.471
Slightly volatile
Net Debt To EBITDA0.10.111.8175
Slightly volatile
Current Ratio0.320.3412.3483
Slightly volatile
Receivables Turnover2.252.3713.1174
Very volatile
Debt To Equity0.04260.04790.0522
Slightly volatile
Capex Per Share0.190.20.5811
Slightly volatile
Revenue Per Share0.0060.00630.3364
Pretty Stable
Interest Debt Per Share0.640.560.7124
Slightly volatile
Debt To Assets0.0390.04390.0478
Slightly volatile
Operating Cycle16816076.7283
Slightly volatile
Days Of Payables Outstanding57.3849.5456.269
Slightly volatile
Ebt Per Ebit1.111.141.0381
Pretty Stable
Long Term Debt To Capitalization0.04040.04550.0496
Slightly volatile
Total Debt To Capitalization0.04040.04550.0496
Slightly volatile
Debt Equity Ratio0.04260.04790.0522
Slightly volatile
Quick Ratio0.320.3412.3483
Slightly volatile
Net Income Per E B T0.810.960.9904
Pretty Stable
Cash Ratio0.290.3112.2157
Slightly volatile
Days Of Inventory Outstanding0.00.00.0
Slightly volatile
Days Of Sales Outstanding16816076.7283
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio2.061.181.9632
Slightly volatile
Debt Ratio0.0390.04390.0478
Slightly volatile
Price Sales Ratio394375241
Slightly volatile
Asset Turnover0.02090.0220.0333
Very volatile

Checkpoint Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap46.9 M49.4 M103 M
Very volatile
Enterprise Value77.3 M43.7 M82.2 M
Pretty Stable

Checkpoint Fundamental Market Drivers

Forward Price Earnings8.8183
Cash And Short Term Investments4.9 M

Checkpoint Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Checkpoint Therapeutics Financial Statements

Checkpoint Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Checkpoint Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Checkpoint Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Checkpoint Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue92.7 K88.1 K
Cost Of Revenue50.1 M32 M
Stock Based Compensation To Revenue 25.31  26.58 
Sales General And Administrative To Revenue 75.89  79.68 
Research And Ddevelopement To Revenue 380.67  399.71 
Capex To Revenue 0.27  0.25 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(582.23)(553.12)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY